Evidence map›Paper›PMID 29535350›Full record

ArticleScientific reports2018

TGF-β1 promotes cell barrier function upon maturation of corneal endothelial cells.

Véronique Beaulieu Leclerc, Olivier Roy, Kim Santerre, Stéphanie Proulx

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Regenerative therapy · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. The Human Tissue-Engineered Cornea (hTEC): Recent Progress.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Véronique Beaulieu LeclercCentre de recherche du Centre hospitalier universitaire (CHU) de Québec - Université Laval, axe médecine régénératrice, Hôpital du Saint-Sacrement, Québec, QC, Canada.
Olivier RoyCentre de recherche du Centre hospitalier universitaire (CHU) de Québec - Université Laval, axe médecine régénératrice, Hôpital du Saint-Sacrement, Québec, QC, Canada.
Kim SanterreCentre de recherche du Centre hospitalier universitaire (CHU) de Québec - Université Laval, axe médecine régénératrice, Hôpital du Saint-Sacrement, Québec, QC, Canada.
Stéphanie ProulxCentre de recherche du Centre hospitalier universitaire (CHU) de Québec - Université Laval, axe médecine régénératrice, Hôpital du Saint-Sacrement, Québec, QC, Canada. stephanie.proulx@fmed.ulaval.ca.
Université Laval · CAHôpital du Saint-Sacrement · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human corneal endothelial cells (HCECs) easily become fibroblastic-like when cultured, rendering them unsuitable for tissue engineering of the cornea. Transforming growth factor β (TGF-β) could be a key factor in this phenomenon; however, TGF-β is also known to maintain the endothelium in a quiescent state in vivo. This work aimed to compare the effects of TGF-β1 on the phenotype of HCECs during the proliferation and maturation phases. Our results show that addition of TGF-β1 during the active proliferation phase produced fibroblastic HCECs and loss of the cell junction markers ZO-1 and n-cadherin, independent from the presence of epidermal growth factor (EGF). By contrast, addition of TGF-β1 in maturation media containing few mitogens led to an endothelial phenotype and functional cell junctions as HCECs developed a high trans-endothelial resistance. Furthermore, addition of AG-1478, an epithelial growth factor receptor inhibitor, enhanced the gain of the endothelial phenotype and cell barrier function. Overall, these results show that TGF-β1 can be used to promote the formation of a typical leaky endothelial barrier during the maturation phase of cultured HCECs. A two-phase culture of HCECs using distinct proliferation and maturation media could also be key for developing ideal HCEC culture conditions.

Indexed as

AdultAgedAntigens, CDBenzamidesCadaverCadherinsCell Culture TechniquesCell ProliferationCells, CulturedDioxolesEndothelial CellsEndothelium, CornealHumansIntercellular JunctionsMiddle AgedPhenotype4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideAntigens, CDBenzamidesCadherinsCDH2 protein, humanDioxolesQuinazolinesRTKI cpdTJP1 protein, humanTransforming Growth Factor beta1TyrphostinsZonula Occludens-1 Protein

Identifiers

PMID29535350
PMCPMC5849742
OpenAlexW2791975532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.